OVARIAN CARCINOSARCOMA
Clinical trials for OVARIAN CARCINOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new OVARIAN CARCINOSARCOMA trials appear
Sign up with your email to follow new studies for OVARIAN CARCINOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could your own tumor cells fight cancer? new trial tests immune cell therapy
Disease control OngoingThis phase 2 trial tests a treatment called LN-145, made from a patient's own immune cells taken from their tumor. These cells are grown in a lab and then given back to the patient to attack the cancer. The study includes people with ovarian cancer, triple-negative breast cancer,…
Matched conditions: OVARIAN CARCINOSARCOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo shows promise for tough ovarian cancers
Disease control OngoingThis study tests whether adding an experimental drug (AZD1775) to standard chemotherapy (gemcitabine) helps women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 124 women will be randomly assigned to receive eith…
Matched conditions: OVARIAN CARCINOSARCOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug combo shows promise for rare, aggressive uterine cancer
Disease control OngoingThis study tests whether combining two drugs, pembrolizumab and lenvatinib, can shrink tumors or slow cancer growth in people with advanced uterine or ovarian carcinosarcoma, a rare and aggressive cancer. About 40 participants will receive the treatment, and researchers will also…
Matched conditions: OVARIAN CARCINOSARCOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Gene-Guided drug cocktail shows promise for Tough-to-Treat gynaecological cancers
Disease control OngoingThis phase 2 trial tests a new drug (ceralasertib) alone or combined with either olaparib or durvalumab in 174 people whose gynaecological cancer has returned. The study groups patients by their cancer type and whether they have a change in the ARID1A gene. The goal is to see if …
Matched conditions: OVARIAN CARCINOSARCOMA
Phase: PHASE2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC